Company profile

Orano Med Theranostics, SAS

Privately held: no public share price (Subsidiary of the French Orano Group; carries no separate public listing. Parent: Orano Group (Orano SA). [resolved 2026-08-05 by resolve-null-is-public; source: https://www.orano.group/en/news/news-group/2024/november/orano-med-lays-foundations-for-its-new-facility-to-produce-precursors-for-its-future-lead-212-radioligand-therapies]) · France

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Pb-DOTAM-GRPR1
Phase 1
Gastrin-releasing peptide receptor (GRPR)Radiopharmaceutical
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.